Three-volunteer Phase I study
In a single-blind, alternating-day, placebo-controlled pilot Phase I study in 3 healthy male volunteers (subcutaneous MT-II, with the dose raised step by step over 2 weeks), the study confirmed dose-dependent skin tanning and documented dose-limiting nausea, flushing and spontaneous penile erections as the primary adverse or incidental effects.
- Study type
- Human trial
- Population
- Human, healthy male volunteers, n=3
- Source
- 1 Dorr et al., 1996
Limitation: Extremely small sample (n=3), single-centre, pilot-stage design, not replicated at scale in a larger controlled trial since.
Limitations in full
Extremely small sample (n=3), single-centre, pilot-stage design, not replicated at scale in a larger controlled trial since. This is the foundational human dosing study for the compound and should be presented as historically important but far too small to support any strength-of-evidence claim beyond Preliminary.